Envestnet Portfolio Solutions Inc. Has $6.66 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Envestnet Portfolio Solutions Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,357 shares of the medical instruments supplier’s stock after purchasing an additional 698 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Becton, Dickinson and Company were worth $6,660,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BDX. Bank of Jackson Hole Trust acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $25,000. Sierra Ocean LLC acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $29,000. Picton Mahoney Asset Management raised its stake in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares in the last quarter. Hopwood Financial Services Inc. acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at $39,000. Finally, Versant Capital Management Inc raised its stake in shares of Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 73 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Finally, Barclays upped their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Stock Up 0.8 %

Shares of NYSE:BDX opened at $227.84 on Tuesday. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company’s 50-day moving average price is $232.72 and its two-hundred day moving average price is $232.19. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The firm has a market cap of $65.42 billion, a P/E ratio of 37.85, a P/E/G ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the transaction, the executive vice president now owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,363 shares of company stock valued at $1,676,105 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.